Barbara Ryan Sells 1,500 Shares of MiNK Therapeutics (NASDAQ:INKT) Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $12.76, for a total value of $19,140.00. Following the transaction, the director directly owned 21,969 shares in the company, valued at approximately $280,324.44. This trade represents a 6.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Barbara Ryan also recently made the following trade(s):

• On Tuesday, March 10th, Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock. The stock was sold at an average price of $15.40, for a total value of $20,020.00.
• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $2,034.00.

MiNK Therapeutics Stock Down 6.9%

Shares of NASDAQ INKT opened at $11.87 on Friday. The business’s 50 day moving average price is $11.41 and its two-hundred day moving average price is $11.37. The company has a market cap of $59.11 million, a PE ratio of -4.18 and a beta of 0.47. MiNK Therapeutics, Inc. has a twelve month low of $6.80 and a twelve month high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last posted its earnings results on Friday, May 15th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.20. As a group, research analysts anticipate that MiNK Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INKT has been the topic of a number of analyst reports. Weiss Ratings raised MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.00.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC grew its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell?to?cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor?associated macrophages and boost T cell–mediated tumor clearance.